IRX-5183

DB05653InvestigationalSmall molecule

Investigated for use/treatment in adverse effects (chemotherapy) and blood (blood forming organ disorders, unspecified).

Mechanism: VTP-195183 is a retinoic acid receptor alpha (RARalpha) specific agonist.
Curator reviewed
Primary indication: Investigated for use/treatment in adverse effects (chemotherapy) and blood (blood forming organ disorders, unspecified).Curator reviewed
Formula / weight: C₂₂H₂₂ClF₂NO₄ · 437.87 g/mol (avg)
Code names: AGN-195183 · NRX-195183 · VTP-195183 · VTP-5183

Resolves to

Compound

Structure

InChIKeyPNAWUIKCVQSLFG-UHFFFAOYSA-NSMILESCC1(C)CCC(C)(C)C2=C1C=C(C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1)C(O)=C2Cl

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with IRX-5183, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.